Transtek(SZ:300562) Xin Lang Zheng Quan·2025-09-11 13:40Core Viewpoint - The resignation of Huang Linxiang from all positions at Lexin Medical marks a significant leadership change, with Wu Rong appointed as the new CFO, indicating a shift in the company's financial management strategy [1][2]. Group 1: Personnel Changes - Huang Linxiang has resigned from all positions, including CFO, employee representative director, and committee member, effective September 9, 2025 [2]. - Huang held 95,000 shares in the company, including 40,000 restricted shares from the 2023 incentive plan, which will be repurchased and canceled by the company [2]. - Wu Rong, previously a member of the fourth supervisory board, has been appointed as the new CFO, bringing extensive experience in financial management within the company [2][3]. Group 2: Financial Performance - In the first half of 2025, Lexin Medical reported a revenue of 521 million yuan, representing a year-on-year growth of 4.57% [3]. - The net profit attributable to shareholders for the same period was 42 million yuan, showing a year-on-year increase of 21.35% [3].